Company Filing History:
Years Active: 1996-1997
Title: Innovations and Contributions of Inventor Andre Bourque
Introduction: Andre Bourque, a distinguished inventor based in Marlboro, MA, has made significant strides in the field of biotechnology. With two patents to his name, Bourque's work focuses on advancing methods for analyzing and detecting oligonucleotides, paving the way for new applications in biological research and medical diagnostics.
Latest Patents: Andre Bourque's recent innovations include the following patents:
1. **Method for Analyzing Oligonucleotide Analogs** - This patent discloses a substrate useful for separating unmodified and modified mononucleotides and oligonucleotides. The substrate is characterized by containing at least 12% (weight:volume) polymer in at least 5M urea and at least 32% (volume:volume) organic solvent. The organic solvent is a chemically stable liquid at room temperature, possessing a dielectric constant of at least 20. The technique enables effective separation of unmodified and modified oligonucleotides using this substrate.
2. **Method for Detecting Charged Oligonucleotides in Biological Fluids** - This innovative method involves detecting and quantifying oligonucleotides with charged internucleotide linkages in biological fluids. The process includes contacting a biological fluid sample with an anion exchange resin at temperatures ranging from 40°C to 65°C. After allowing sufficient adsorption time, the oligonucleotides are desorbed using a buffer with a salt concentration of 1 M to 2.5 M and a pH between 6.5 and 7.5. The released oligonucleotides are then detected and quantified.
Career Highlights: Andre Bourque has been a vital asset to Hybridon, Inc., where he applies his expertise in biotechnology to develop groundbreaking methodologies. His work not only contributes to the company's ongoing research but also enhances the understanding of oligonucleotide behavior in biological samples.
Collaborations: Throughout his career, Andre has collaborated with notable colleagues, including Aharon S Cohen and Maria Vilenchik. These partnerships have reinforced the innovative environment at Hybridon, Inc. and have facilitated the advancement of methodologies in oligonucleotide analysis.
Conclusion: Andre Bourque's impact on biotechnology through his innovative patents showcases his dedication to advancing scientific research. His contributions at Hybridon, Inc. reflect a commitment to excellence in developing methods that enhance the detection and analysis of oligonucleotides, furthering the potential for breakthroughs in medical and biological applications.